John Kefer, MD
Urology · Boulder, CONPI 1174799837
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,438 of the $68,473 with a category attached, or 62.0%. Teleflex LLC accounts for 67.5% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $43,117 and has fallen 94.5% since, to $2,356 in 2025. Among urology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $234.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$46K
- Medtronic$12K
- Angiodynamics, Inc.$3K
- Neotract Inc.$1K
- Johnson & Johnson$1K
- Sumitomo Pharma America, Inc.$648
- plus $4K from 30 others
Across 4 payments — averaging $631.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$3K
What the payments were for
- Consulting fees$11,63317%
- Speaking & faculty fees$42,43862%
- Travel & lodging$4,9687%
- Food & beverage$9,31114%
- Education$1240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 52 | $46,232 |
| Medtronic(2 entities) | 10 | $12,351 |
| Angiodynamics, Inc. | 16 | $2,981 |
| Neotract Inc. | 16 | $1,383 |
| Johnson & Johnson | 20 | $1,289 |
| Sumitomo Pharma America, Inc. | 27 | $648 |
| AbbVie(2 entities) | 34 | $623 |
| Pfizer | 19 | $406 |
| Axonics, Inc. | 13 | $285 |
| Astellas Pharma US Inc | 8 | $279 |
| Boston Scientific | 12 | $258 |
| Ferring Pharmaceuticals Inc. | 4 | $233 |
| Myovant Sciences Inc. | 11 | $180 |
| Olympus America Inc. | 3 | $169 |
| Bayer | 7 | $141 |
| Telix Pharmaceuticals | 6 | $137 |
| Progenics Pharmaceuticals, Inc. | 1 | $79 |
| Urogen Pharma, Inc. | 4 | $78 |
| Convatec Inc. | 2 | $75 |
| Laborie Medical Technologies Corp. | 3 | $70 |
| Tolmar, Inc. | 3 | $63 |
| Coloplast | 2 | $61 |
| Baxter Healthcare | 2 | $60 |
| Dendreon Pharmaceuticals LLC | 2 | $60 |
| Novartis | 2 | $57 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $55 |
| Rochester Medical Corporation | 2 | $40 |
| Novo Nordisk | 1 | $28 |
| Tempus AI, Inc | 1 | $25 |
| Endo Pharmaceuticals Inc. | 1 | $22 |
| Cook Medical LLC | 1 | $22 |
| Steris Corporation | 1 | $21 |
| Antares Pharma, Inc. | 1 | $19 |
| Merck | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $16 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$46,845
- VALLEYLAB FT10$10,708
- Nanoknife$2,710
- LigaSure$1,000
- Erleada$796
- ADSTILADRIN$155
- BOTOX$145
- iTIND System$122
How this compares
$68,473 in reported general payments places this provider in the 95th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 133 | $1,833,677 |
| OrgovyxRelugolix | 215 | $567,819 |
| ErleadaApalutamide | 11 | $107,040 |
| GemtesaVibegron | 35 | $25,289 |
| MyrbetriqMirabegron | 26 | $22,374 |
| Abiraterone Acetate | 31 | $8,586 |
| Tamsulosin Hcl | 280 | $2,905 |
| Tolterodine Tartrate | 43 | $2,803 |
| Potassium Citrate ErPotassium Citrate | 27 | $1,876 |
| Oxybutynin Chloride | 91 | $1,186 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 74 | $956 |
| Silodosin | 14 | $773 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 43 | $681 |
| Solifenacin Succinate | 12 | $415 |
| Finasteride | 41 | $409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $279 | $1,856,051159 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $648 | $593,107250 claims |
| Johnson & JohnsonErleada | $1,289 | $107,04011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 urology providers in Colorado.
Other urology in Boulder
- John WebsterBoulder$25K
- James ClarkBoulder$9K
- Stephen SiegelBoulder$7K
- Lawrence KarshDenver$706K
- Alexandra RogersLafayette$476K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Damian SorceParker$224K
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.